MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar ipsiety (< 20) Submitted: 6/22/2011 2:55:43 PM : Underperform Start Price: $4.07 MNKD Score: +50.90

Speculation at the moment.

Report this Post Reply

Featured Broker Partners


Advertisement